Factors affecting insulin adherence to type I glass bottles

Mitrano, Francis P.; Newton, David William

doi:10.1093/ajhp/39.9.1491

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin is adsorbed in a monolayer to a fixed number of binding sites for a given infusion apparatus. 15–17,19,20 Insulin adsorption occurs rapidly; however, at low flow rates binding sites in the extension tubing will remain free until a sufficient volume of infusate has flowed through the tubing. This may explain our findings of strikingly poor initial insulin delivery at lower flow rates and concentrations, with insulin delivery rising once all the insulin binding sites on the tubing have been occupied.…”

Section: Discussionmentioning

confidence: 99%

Insulin infusions in the neonatal unit: Delivery variation due to adsorption

Hewson

Nawadra

Oliver

et al. 2000

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Insulin infusions in the neonatal unit: Delivery variation due to adsorption

Hewson

Nawadra

Oliver

et al. 2000

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…Insulin has binding affinity for hydrophobic (Hirsch et al, 1981) as well as hydrophilic surfaces (Mitrano and Newton, 1982), although more insulin is adsorbed onto hydrophobic than onto hydrophilic materials (Sefton and Antonacci, 1984). Insulin has binding affinity for hydrophobic (Hirsch et al, 1981) as well as hydrophilic surfaces (Mitrano and Newton, 1982), although more insulin is adsorbed onto hydrophobic than onto hydrophilic materials (Sefton and Antonacci, 1984).…”

Section: Insulin Pumpsmentioning

confidence: 99%

Protein Delivery

2002

Pharmaceutical Biotechnology

View full text Add to dashboard Cite

A major challenge confronting pharmaceutical scientists in the future will be to design successful dosage forms for the next generation of drugs. Many of these drugs will be complex polymers of amino acids (e.g., peptides, proteins), nucleosides (e.g., antisense molecules), carbohydrates (e.g., polysaccharides), or complex lipids.Through rational drug design, synthetic medicinal chemists are preparing very potent and very specific peptides and antisense drug candidates. These molecules are being developed with molecular characteristics that permit optimal interaction with the specific macromolecules (e.g., receptors, enzymes, RNA, DNA) that mediate their therapeutic effects. Rational drug design does not necessarily mean rational drug delivery, however, which strives to incorporate into a molecule the molecular properties necessary for optimal transfer between the point of administration and the pharmacological target site in the body.Like rational drug design, molecular biology is having a significant impact on the pharmaceutical industry. For the first time, it is possible to produce large quantities of highly pure proteins, polysaccharides, and lipids for possible pharmaceutical applications. Like peptides and antisense molecules, the design of successful dosage forms for these complex biotechnology products represents a major challenge to pharmaceutical scientists.Development of an acceptable drug dosage form is a complex process requiring strong interactions between scientists from many different divisions in a pharmaceutical company, including discovery, development, and manufacturing. The series editor, the editors of the individual volumes, and the publisher hope that this new series will be particularly helpful to scientists in the development areas of a pharmaceutical company (e.g., drug metabolism, toxicology, pharmacokinetics and pharmacodynamics, drug ix x Preface to the Series delivery, preformulation, formulation, and physical and analytical chemistry). In addition, we hope this series will help to build bridges between the development scientists and scientists in discovery (e.g., medicinal chemistry, pharmacology, immunology, cell biology, molecular biology) and in manufacturing (e.g., process chemistry, engineering). The design of successful dosage forms for the next generation of drugs will require not only a high level of expertise by individual scientists, but also a high degree of interaction between scientists in these different divisions of a pharmaceutical company.Finally, everyone involved with this series hopes that these volumes will also be useful to the educators who are training the next generation of pharmaceutical scientists. In addition to having a high level of expertise in their respective disciplines, these young scientists will need to have the scientific skills necessary to communicate with their peers in other scientific disciplines. RONALD T. BORCHARLDT Series Editorxi xii Preface sometimes unanticipated formulation challenges. Such problems have plagued efforts to develop ...

show abstract

Insulin Formulation and Delivery

Brange

Langkjaer

2002

Pharmaceutical Biotechnology

View full text Add to dashboard Cite

Factors affecting insulin adherence to type I glass bottles

Cited by 3 publications

References 0 publications

Insulin infusions in the neonatal unit: Delivery variation due to adsorption

Insulin infusions in the neonatal unit: Delivery variation due to adsorption

Protein Delivery

Insulin Formulation and Delivery

Contact Info

Product

Resources

About